$223 Million is the total value of Boxer Capital, LLC's 28 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 39.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLVS | Buy | CLOVIS ONCOLOGY INC | $36,050,000 | +483.9% | 1,000,000 | +122.2% | 16.16% | +195.2% |
| MDCO | New | MEDICINES COMPANY | $26,418,000 | – | 700,000 | +100.0% | 11.84% | – |
| BPMC | BLUEPRINT MEDICINES CORP | $20,943,000 | +46.7% | 705,159 | 0.0% | 9.39% | -25.9% | |
| New | MEDICINES COMPANYcall | $20,749,000 | – | 549,800 | +100.0% | 9.30% | – | |
| BGNE | BEIGENE LTDsponsored adr | $15,209,000 | +3.4% | 493,630 | 0.0% | 6.82% | -47.7% | |
| SGEN | SEATTLE GENETICS INC | $12,563,000 | +33.7% | 232,600 | 0.0% | 5.63% | -32.4% | |
| AVXS | Buy | AVEXIS INC | $12,353,000 | +127.7% | 299,756 | +110.1% | 5.54% | +15.1% |
| AQXP | AQUINOX PHARMACEUTICALS INC | $11,727,000 | +101.8% | 877,753 | 0.0% | 5.26% | +2.0% | |
| INCY | INCYTE CORP | $9,429,000 | +17.9% | 100,000 | 0.0% | 4.23% | -40.4% | |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $9,252,000 | +69.9% | 100,000 | +42.9% | 4.15% | -14.1% |
| ARDMQ | Sell | ARADIGM CORP | $6,402,000 | +33.0% | 930,513 | -15.5% | 2.87% | -32.8% |
| New | ACADIA PHARMACEUTICALS INC | $6,392,000 | – | 200,938 | +100.0% | 2.86% | – | |
| MRTX | MIRATI THERAPEUTICS INC | $5,010,000 | +21.1% | 757,935 | 0.0% | 2.24% | -38.8% | |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $4,959,000 | +217.7% | 1,351,137 | +93.0% | 2.22% | +60.6% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $3,551,000 | +53.9% | 234,220 | 0.0% | 1.59% | -22.2% | |
| TSRO | Sell | TESARO INC | $3,508,000 | -44.4% | 35,000 | -53.3% | 1.57% | -71.9% |
| HRTX | New | HERON THERAPEUTICS INC | $3,446,000 | – | 200,000 | +100.0% | 1.54% | – |
| KURA | Sell | KURA ONCOLOGY INC | $3,333,000 | +94.1% | 533,251 | -15.9% | 1.49% | -1.8% |
| ALDX | ALDEYRA THERAPEUTICS INC | $2,286,000 | +38.0% | 291,230 | 0.0% | 1.02% | -30.2% | |
| EBIO | Sell | ELEVEN BIOTHERAPEUTICS INC | $2,100,000 | +25.7% | 750,000 | -25.0% | 0.94% | -36.5% |
| EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $1,852,000 | +0.1% | 138,331 | +48.2% | 0.83% | -49.4% |
| ARRY | New | ARRAY BIOPHARMA INC | $1,350,000 | – | 200,000 | +100.0% | 0.60% | – |
| NBRV | NABRIVA THERAPEUTICS AGsponsored adr | $1,246,000 | -6.0% | 176,710 | 0.0% | 0.56% | -52.5% | |
| AKTX | AKARI THERAPEUTICS PLCsponsored adr | $1,191,000 | -36.9% | 139,899 | 0.0% | 0.53% | -68.1% | |
| ONTX | New | ONCONOVA THERAPEUTICS INC | $838,000 | – | 316,386 | +100.0% | 0.38% | – |
| NVET | NEXVET BIOPHARMA PUB LTD CO | $643,000 | -10.7% | 154,840 | 0.0% | 0.29% | -54.9% | |
| ONTXW | New | ONCONOVA THERAPEUTICS INC*w exp 07/07/202 | $242,000 | – | 241,644 | +100.0% | 0.11% | – |
| ESSA PHARMA INC | $74,000 | -10.8% | 28,100 | 0.0% | 0.03% | -55.4% | ||
| ACHC | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -200,938 | -100.0% | -5.78% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -20,000 | -100.0% | -6.19% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Aviva Holdings Ltd. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.